Liporaxel demonstrated non-inferiority in progression-free survival and superiority in general survival in comparison with intravenous paclitaxel as a second-line remedy for sufferers with...
Sufferers with BRAF V600E-mutant metastatic colorectal most cancers had poor scientific outcomes, with a median general survival of 17 months, no matter whether...
Amongst sufferers with BRAF V600E-mutant metastatic colorectal most cancers (mCRC), early findings from the section 3 BREAKWATER scientific trial recommend a sustained survival...
Findings from a lately introduced examine demonstrated that sufferers with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors (GEP-NETs) might profit from therapy with Afinitor...
(ctDNA) positivity after surgical procedure for stage 3 colon most cancers predicted poorer disease-free survival, however sufferers with ctDNA who acquired Celebrex had...
